With 1.06 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.25 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $24.6464 whereas the lowest price it dropped to was $23.81. The 52-week range on CPRX shows that it touched its highest point at $26.16 and its lowest point at $14.47 during that stretch. It currently has a 1-year price target of $34.00. Beta for the stock currently stands at 0.70.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CPRX was up-trending over the past week, with a rise of 4.66%, but this was up by 1.46% over a month. Three-month performance surged to 4.66% while six-month performance rose 11.02%. The stock gained 59.36% in the past year, while it has gained 16.29% so far this year. A look at the trailing 12-month EPS for CPRX yields 1.31 with Next year EPS estimates of 1.68. For the next quarter, that number is 0.34. This implies an EPS growth rate of 8.65% for this year and 18.27% for next year. EPS is expected to grow by 12.45% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 34.27%.
Float and Shares Shorts:
At present, 120.88 million CPRX shares are outstanding with a float of 111.11 million shares on hand for trading. On 2025-04-15, short shares totaled 7.79 million, which was 639.0 higher than short shares on 1741910400. In addition to Mr. Richard John Daly M.B.A. as the firm’s President, CEO & Director, Mr. Michael W. Kalb CPA serves as its Executive VP, Treasurer & CFO.
Institutional Ownership:
Through their ownership of 0.82793 of CPRX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, CPRX reported revenue of $141820000.0 and operating income of $62843000.0. The EBITDA in the recently reported quarter was $65579000.0 and diluted EPS was $0.44.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CPRX since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CPRX analysts setting a high price target of 40.0 and a low target of 31.0, the average target price over the next 12 months is 34.0. Based on these targets, CPRX could surge 64.81% to reach the target high and rise by 27.73% to reach the target low. Reaching the average price target will result in a growth of 40.09% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $1.22763 being high and $1.18591 being low. For CPRX, this leads to a yearly average estimate of $1.21571.
